

Peer-reviewed publications:

1. Olszewski AJ, Desai A. Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. *Int J Radiat Oncol Biol Phys.* 2014 Jan 7. pii: S0360-3016(13)03583-9. doi: 10.1016/j.ijrobp.2013.11.225
2. Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. *Ann Hematol.* 2013 Sep 22. doi: 10.1007/s00277-013-1900-4
3. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database. *Am J Hematol.* 2013 Nov 23. doi: 10.1002/ajh.23638.
4. Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis. *Int J Cancer.* 2013 Nov 22. doi: 10.1002/ijc.28625.
5. Shafqat H, Alquadan KF, Olszewski AJ. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. *Osteoporos Int.* 2013 Oct 25.
6. Ali S, Olszewski AJ. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study. *Leuk Lymphoma.* 2013 Sep 25. doi:10.3109/10428194.2013.847938
7. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. *Cancer.* 2013 Jul 30. doi: 10.1002/cncr.28264.
8. Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. *Ann Oncol.* 2013 May;24(5):1352-9. doi: 10.1093/annonc/mds644
9. Olszewski AJ, Migdady Y, Boolbol S, Klein P, Boachie-Adjei K, Sakr B, et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. *Breast Cancer Research and Treatment.* 2013:1-9. doi: 10.1007/s10549-013-2423-3
10. Migdady Y, Sakr BJ, Sikov WM, Olszewski AJ. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: Application and outcomes. *Breast.* 2013 Mar 9. pii: S0960-9776(13)00047-7. doi: 10.1016/j.breast.2013.02.014.
11. Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G-FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. *J Gastrointest Cancer.* 2012 Dec 4. doi: 10.1007/s12029-012-9466-2
12. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. *Cancer.* 2013 Feb 1;119(3):629-38. doi: 10.1002/cncr.27773.
13. Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. *Am J Hematol.* 2012 Nov;87(11):E119-22. doi: 10.1002/ajh.23314.
14. Desai A, Telang GH, Olszewski AJ. Remission of primary cutaneous anaplastic large cell

- lymphoma after a brief course of brentuximab vedotin. *Ann Hematol.* 2013 Apr;92(4):567-8. DOI: 10.1007/s00277-012-1610-3.
15. Migdady Y, Olszewski AJ. Evaluation of incidental neutropenia in a multi-ethnic setting. *Int J Lab Hematol.* 2013, 35: e6–e8. DOI: 10.1111/ijlh.12016.
 16. Gavini A, Telang G, Olszewski AJ. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. *Int J Hematol.* 2012 Jan 31: DOI: 10.1007/s12185-012-1012-2.
 17. Casey DJ, Kim AY, Olszewski AJ. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma. *Am J Hematol.* 2012 May;87(5):521-4.. DOI: 10.1002/ajh.22239
 18. Migdady Y, Olszewski AJ. Paroxysmal Nocturnal Hemoglobinuria Presenting with a Left Intraventricular Thrombus in a Patient with Prior Thymoma and Aplastic Anemia. *Clinical Medicine Insights: Oncology* 2011;5 343-348. doi: 10.4137/CMO.S8442
 19. Olszewski AJ, Grossbard ML, Kozuch P. The Horizon of Antiangiogenic Therapy for Colorectal Cancer. *Oncology (Williston Park):* March 2005;19(3): 297.
 20. Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from rituximab. *Science STKE.* 2004 Jul 6;2004(241):PE30.
 21. Olszewski AJ, Shapiro JM. Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection. *J Intensive Care Med.* 2003 May-Jun;18(3):156-9.
 22. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. *Science.* 2000 Apr 14;288(5464):335-9. DOI: [10.1126/science.288.5464.335](https://doi.org/10.1126/science.288.5464.335)

Abstracts:

1. Khan H, Somasundar P, Olszewski AJ. Nodal involvement and impact of adequate staging in older patients with resectable colon cancer: A population-based analysis. *J Clin Oncol* 32, 2014 (suppl 3; abstr 424). 2014 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 16-18 January, 2014—poster presentation.
2. Olszewski AJ, Ali S, Shafqat H. Survival After Rituximab-Based Chemoimmunotherapy In Older Patients With Follicular, Nodal Marginal Zone and Small Lymphocytic Lymphoma: Analysis Of SEER-Medicare Data. *Blood* 2013 122:1736. American Society of Hematology Annual Meeting, New Orleans, LA. December 2013—poster presentation.
3. Migdady Y, Salhab M, Olszewski AJ. Living In Remission: Disparities In Conditional Survival Among Non-Hodgkin Lymphoma Survivors. *Blood* 2013 122:2915. American Society of Hematology Annual Meeting, New Orleans, LA. December 2013—poster presentation.
4. Desai A, Olszewski AJ. Evaluation of the physician-patient communication assessment tool (CAT) in a hematology-oncology practice. *J Clin Oncol* 31, 2013 (suppl 31; abstr 14)—2013 ASCO Quality Care Symposium—poster presentation, San Diego, CA, November 2013.
5. Olszewski AJ. Comparative outcomes of splenectomy and rituximab-based chemotherapy in elderly patients with splenic marginal zone lymphoma. *J Clin Oncol* 31, 2013 (suppl; abstr 8549) ASCO 2013 – poster presentation.

6. Ali S, Olszewski AJ. Nodular lymphocyte-predominant and classical Hodgkin lymphoma subtypes: Differences in biology, survival, and impact of radiotherapy. *J Clin Oncol* 31, 2013 (suppl; abstr 8550) ASCO 2013 – poster presentation.
7. Bishop K, Olszewski AJ. Melanoma of ocular, mucosal, and genital sites: Epidemiology and survival outcomes. *J Clin Oncol* 31, 2013 (suppl; abstr 9051) ASCO 2013 – poster presentation.
8. Taber AM, Khurshid H, Perez K, Birnbaum AE, Olszewski AJ, Luppe D, Jean M, Rosati K, Safran H. Phase I study of ridaforolimus with cetuximab for patients with advanced non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancer. *J Clin Oncol* 31, 2013 (suppl; abstr 8075) ASCO 2013 – poster presentation.
9. Austin TC, Perez K, Fontes-Borts L, Luppe D, Jean M, Olszewski AJ, Rosati K, Rathore B, Safran H. A phase II study of cabazitaxel in patients with previously treated metastatic gastroesophageal adenocarcinoma. *J Clin Oncol* 31, 2013 (suppl; abstr e15095) ASCO 2013
10. Shao T, Olszewski AJ, Boolbol SK, Migdady Y, Boachie-Adjei K, Sakr BJ, Klein P, Sikov W. Disease-related outcomes with adjuvant chemotherapy in HER2 positive or triple negative T1a/bN0 breast cancers. San Antonio Breast Cancer Symposium 2012, Abstr. P6-07-34. doi: [10.1158/0008-5472.SABCS12-P6-07-34](https://doi.org/10.1158/0008-5472.SABCS12-P6-07-34)
11. Olszewski AJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: Analysis of the surveillance, epidemiology and end results (SEER)-Medicare database. ASCO GI 2013, Abstr.75 (poster presentation, accepted)
12. Perez K, Pricolo V, Vrees M, Dipetrillo T, Oldenberg N, Klipfel A, Schecter S, Kinsella T, Roth L, Cataldo T, Shah N, Olszewski A, Isdale D, Safran H, Sikov W: A Phase II Study of Complete Neoadjuvant Therapy in Rectal Cancer (CONTRE): The Brown University Oncology Group. ASCO GI 2013, Abstr.335)
13. Desai A, Kuritzky B, Castillo JJ, Olszewski AJ: Vertebral Compression Fractures in Patients with Chronic Lymphocytic Leukemia: Incidence and Risk Factors. (ASH 2012, Abstr 4586).
14. Olszewski AJ, Desai A: Radiotherapy in Stage I and II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT): Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. (ASH 2012, Abstr. 2053, poster presentation).
15. Olszewski AJ. Survival with splenectomy in splenic marginal zone lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. *J Clin Oncol* 30, 2012 (suppl; abstr 8044) (ASCO 2012)
16. Castillo JJ, Olszewski AJ. Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. *J Clin Oncol* 30, 2012 (suppl; abstr 8045) (ASCO 2012)
17. Migdady Y, Sikov WM, Sakr BJ, Olszewski AJ. Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer. *J Clin Oncol* 30, 2012 (suppl; abstr 1034) (ASCO 2012)
18. Olszewski AJ, Malamud S, Grossbard ML, Mirzoyev T, Dietrich M, Thurakal A, Rodriguez T, Kozuch P. Phase I dose-finding study of biweekly oxaliplatin (E) in combination with gemcitabine (G), 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (G-FLIE) in patients with solid tumors. Proc ASCO 2005: Abs#4202.